# Immunopeptidomics of cutaneous leishmaniasis patients reveals the natural antigenic landscape

## TL;DR

This study identifies naturally presented immune targets in cutaneous leishmaniasis patients, offering insights for vaccine development.

## Contribution

The first comprehensive map of Leishmania immunopeptidome in human disease, revealing conserved antigens for vaccine design.

## Key findings

- Identified 333 MHC-I and 247 MHC-II epitopes from L. aethiopica proteins in CL patients.
- Some peptides were detected in early infection in a monocyte model, indicating early relevance.
- Commonly used prediction tools missed 20–70% of naturally presented epitopes.

## Abstract

Cutaneous leishmaniasis (CL) is a skin disease caused by Leishmania infection, for which no licensed human vaccine exists. Protective immunity is largely T cell–mediated and depends on antigen presentation by MHC molecules, yet the naturally presented epitopes during human disease remain poorly defined.

To address this gap, we performed mass spectrometry–based immunopeptidomics on lesional biopsies from 27 Ethiopian CL patients spanning the full clinical spectrum.

We newly identified 333 MHC-I and 247 MHC-II epitopes from 398 L. aethiopica proteins, including 19 peptides and 51 antigens recurrently presented across patients of which several were also epitope-rich. Some peptides were also detected during early infection in a L. aethiopica–infected THP-1 monocyte model, highlighting their relevance from disease onset. Notably, despite the broad predictive coverage of NetMHCpan and NetMHCIIpan, these tools missed 20–70% of the naturally presented epitopes while predicting millions of candidates, underscoring the limitations of prediction-only vaccine pipelines.

This first comprehensive map of the Leishmania immunopeptidome in human disease reveals conserved and prevalent antigens that can inform rational vaccine design and deepen our understanding of protective T cell responses in leishmaniasis.